

119TH CONGRESS
1ST SESSION

H. R. 679

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JANUARY 23, 2025

Mrs. HARSHBARGER (for herself, Mr. HERN of Oklahoma, Mr. BOST, Mrs. MILLER of Illinois, Mr. WEBER of Texas, Mr. BABIN, Mr. MOOLENAAR, Mr. WEBSTER of Florida, Mr. BAIRD, Mr. HIGGINS of Louisiana, Mr. FEENSTRA, Mr. YAKYM, Mr. BIGGS of Arizona, Mr. PALMER, and Mr. GUEST) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. NULLIFICATION OF MODIFICATIONS TO REMS**
4 **FOR MIFEPRISTONE.**

5 (a) NULLIFICATION.—The modifications made by the
6 Food and Drug Administration in January 2023 to the

1 risk evaluation and mitigation strategy under section 505–
2 1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
3 355–1) for mifepristone are hereby nullified.

4 (b) NO SUBSTANTIALLY SIMILAR PROVISIONS.—The
5 Secretary of Health and Human Services (or any head of
6 any office, department, or agency of the Department of
7 Health and Human Services) shall not establish, imple-
8 ment, or enforce any provision of a risk evaluation and
9 mitigation strategy under section 505–1 of the Federal
10 Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for
11 mifepristone that is substantially similar to any of the
12 modifications nullified by subsection (a).

○